|
Tuesday, April 26, 2022
|
(VIRTUAL WORKSHOP) Challenges and Strategies for Relative Bioavailability Studies on Drug Products Involving Endogenous Substances
|
|
Wednesday, February 23, 2022
|
Webinar Session 6: Challenges and Issues in Meeting Regulatory Requirements for In Vitro Dissolution Testing
|
|
Friday, March 26, 2021
|
Secrets to Successful Pre-IND Meetings for 505(b)(2) NDA Drug Development
|
|
Wednesday, November 18, 2020
|
In Silico Modeling Methods for Generic Drug Products: Applications and Expectations
|
|
Wednesday, June 17, 2020
|
505(b)(2) Webinar Series Session 3: Commercialization Strategies and Considerations for Successful 505(b)(2) NDA Drug Development
|
|
Wednesday, May 13, 2020
|
505(b)(2) Webinar Series Session 1 & 2
|
|
Thursday, April 16, 2020
|
Cutting Edge Approaches for Demonstrating Bioequivalence
|
|
Wednesday, October 16, 2019
|
Demystifying 505(b)(2) Development: Navigating the Scientific, Regulatory, Legal, and Business Complexities
|
|
Thursday, April 04, 2019
|
Challenging Statistical Issues with In Vitro and In Vivo Bioequivalence Studies: Extreme Variability, Special Study Designs and Novel Approaches
|
|
Thursday, October 18, 2018
|
Inaugural SAAMnow Annual Scientific Workshop
|